Human growth hormone produced with recombinant DNA technology

\nHormones affect the metabolism by stimulating the genetic apparatus of the cell, activating enzymes and changing the rate of enzymatic reactions. They increase the formation of informative ribonucleic acid, which determines the structure of the protein, and affect the biosynthesis of proteins. Somatotropin hormone (STG) is a peptide hormone consisting of 192 amino acids and is secreted from the anterior lobe of the pituitary gland. The deficiency of this hormone causes hypophysis. The demand for recombinant somatotropin is likely to increase in the near future. Because current production technologies cannot meet the demand for cheap somatotropin due to limited production capacity and high production cost. As a result, it is necessary to study the mechanisms of production of therapeutic recombinant proteins. Recombinant somatotropin is mainly synthesized using E. coli lemo strain and is used for therapeutic purposes.\n

Publication Details

Journal
Springer Link (Chiba Institute of Technology)
Published
2024-10-09
DOI
https://doi.org/10.1051/bioconf/202413004009/pdf
Primary Topic
Legal and Regulatory Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Human growth hormone produced with recombinant DNA technology

Springer Link (Chiba Institute of Technology)
Legal and Regulatory Analysis
article

Human growth hormone produced with recombinant DNA technology

article en

Abstract

\nHormones affect the metabolism by stimulating the genetic apparatus of the cell, activating enzymes and changing the rate of enzymatic reactions. They increase the formation of informative ribonucleic acid, which determines the structure of the protein, and affect the biosynthesis of proteins. Somatotropin hormone (STG) is a peptide hormone consisting of 192 amino acids and is secreted from the anterior lobe of the pituitary gland. The deficiency of this hormone causes hypophysis. The demand for recombinant somatotropin is likely to increase in the near future. Because current production technologies cannot meet the demand for cheap somatotropin due to limited production capacity and high production cost. As a result, it is necessary to study the mechanisms of production of therapeutic recombinant proteins. Recombinant somatotropin is mainly synthesized using E. coli lemo strain and is used for therapeutic purposes.\n

Springer Link (Chiba Institute of Technology)
Industry, innovation and infrastructure
Openalex Percentile: Top 43%
Legal and Regulatory Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.